GnRH for Luteal Support in IVF/ICSI/FET Cycles

THE STUDY

About this study

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Detailed description

see above

PARTICIPATION

Who may participate

Minimum age: 18 Years
Maximum age: 40 Years
Sex eligibility: Female
Healthy volunteers: Not accepted

Only the study team can confirm eligibility. The registry criteria below are not a medical recommendation.

Full inclusion and exclusion criteria

Inclusion Criteria:

* women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Exclusion Criteria:

* day 3 transfers

NEAR YOU

Study locations worldwide

1 site

Check the individual site’s status and contact the listed study team for current availability.

University Reproductive Associates

Not reported

Hasbrouck Heights, New Jersey, 07604, United States

Contact details are not published in this record. Check official study record ↗

WHAT IS BEING STUDIED

Treatments and study groups

Interventions

GnRHDrug

single shot of GnRH agonist

Study groups: GnRH agonist

placeboDrug

placebo

Study groups: Placebo

Study groups

GnRH agonistExperimental

Not reported.

Interventions: Drug: GnRH

PlaceboPlacebo comparator

Not reported.

Interventions: Drug: placebo

RESEARCH DETAILS

Study design

Study type: Interventional
Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomized
Study model: Parallel
Masking: Quadruple
Enrolment: 350 participants · Estimated
Who is masked: Participant, Care provider, Investigator, Outcomes assessor

TIMELINE & MEASURES

Dates and outcomes

Study started: Nov 2015 · Actual
Primary completion: Jul 2027 · Estimated
Study completion: Nov 2027 · Estimated
First registered: 6 Feb 2015 · Estimated
Last registry update: 19 Oct 2026 · Actual
Status last verified: Oct 2026

Primary outcomes (1)

Live birth per transfer

Not reported.

Time frame: 9 months

Secondary outcomes (3)

implantation rates

Not reported.

Time frame: 4 weeks

clinical pregnancy

Not reported.

Time frame: 4 weeks

rates of OHSS

Not reported.

Time frame: 4 weeks

STUDY TEAM

Sponsor and contacts

Lead sponsor: University Reproductive Associates
Sponsor type: Other
Collaborators: Not reported
Organisation study ID: PRO20140001128

Central study contacts

No central contact is currently reported. Check the site contacts or the official record.

Study officials

Peter G McGovern, MDPrincipal investigator · Rutgers University

Contacts are provided by the registry for study enquiries. Do not use these details for marketing or promotions.

Results, documents and references

No results are posted in this registry record

This does not mean the study has no findings. Results may not yet have been submitted or published here.

No study documents are listed in this record.

Publications (2)

van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD009154. doi: 10.1002/14651858.CD009154.pub2. PubMed ↗
Oliveira JB, Baruffi R, Petersen CG, Mauri AL, Cavagna M, Franco JG Jr. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol. 2010 Sep 8;8:107. doi: 10.1186/1477-7827-8-107. PubMed ↗